Vestal Point Capital, LP Achilles Therapeutics PLC Transaction History
Vestal Point Capital, LP
- $1.34 Trillion
- Q2 2024
A detailed history of Vestal Point Capital, LP transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Vestal Point Capital, LP holds 1,500,000 shares of ACHL stock, worth $1.53 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
1,500,000
Previous 1,500,000
-0.0%
Holding current value
$1.53 Million
Previous $1.88 Billion
34.8%
% of portfolio
0.09%
Previous 0.16%
Shares
2 transactions
Others Institutions Holding ACHL
# of Institutions
29Shares Held
22.2MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$11.3 Million10.58% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.44 Million0.29% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.64 Million0.09% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.47 Million0.48% of portfolio
-
Baker Bros. Advisors LP New York, NY1.11MShares$1.13 Million0.01% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $41.6M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...